
Shik Luen Paul Ip
Examiner (ID: 5172, Phone: (571)272-1941 , Office: P/2837 )
| Most Active Art Unit | 2837 |
| Art Unit(s) | 2837, 1931, 2828, 2107 |
| Total Applications | 3388 |
| Issued Applications | 3093 |
| Pending Applications | 44 |
| Abandoned Applications | 259 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15422567
[patent_doc_number] => 10544197
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-28
[patent_title] => FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
[patent_app_type] => utility
[patent_app_number] => 15/675022
[patent_app_country] => US
[patent_app_date] => 2017-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 5014
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15675022
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/675022 | FGF-23 epitope peptide for improving resistance to breakage and eggshell strength | Aug 10, 2017 | Issued |
Array
(
[id] => 12117313
[patent_doc_number] => 20180000898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'Method of Treating or Ameliorating Type 1 Diabetes Using FGF21'
[patent_app_type] => utility
[patent_app_number] => 15/671923
[patent_app_country] => US
[patent_app_date] => 2017-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 27990
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15671923
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/671923 | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 | Aug 7, 2017 | Abandoned |
Array
(
[id] => 12260612
[patent_doc_number] => 20180079806
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-22
[patent_title] => 'CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY'
[patent_app_type] => utility
[patent_app_number] => 15/668573
[patent_app_country] => US
[patent_app_date] => 2017-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 42675
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668573
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/668573 | CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY | Aug 2, 2017 | Abandoned |
Array
(
[id] => 12051208
[patent_doc_number] => 20170327551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-16
[patent_title] => 'METHODS OF USING COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19 POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A SUBJECT'
[patent_app_type] => utility
[patent_app_number] => 15/666402
[patent_app_country] => US
[patent_app_date] => 2017-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 32583
[patent_no_of_claims] => 74
[patent_no_of_ind_claims] => 14
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666402
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/666402 | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject | Jul 31, 2017 | Issued |
Array
(
[id] => 12624552
[patent_doc_number] => 20180100014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-12
[patent_title] => BINDING PROTEINS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/659177
[patent_app_country] => US
[patent_app_date] => 2017-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72936
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15659177
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/659177 | Beta-klotho binding proteins | Jul 24, 2017 | Issued |
Array
(
[id] => 16169516
[patent_doc_number] => 10711066
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-14
[patent_title] => Anti-canine platelet derived growth factor receptor alpha antibody
[patent_app_type] => utility
[patent_app_number] => 16/318944
[patent_app_country] => US
[patent_app_date] => 2017-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5240
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318944
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/318944 | Anti-canine platelet derived growth factor receptor alpha antibody | Jul 19, 2017 | Issued |
Array
(
[id] => 15256503
[patent_doc_number] => 20190376985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 16/315805
[patent_app_country] => US
[patent_app_date] => 2017-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315805
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | Jul 6, 2017 | Pending |
Array
(
[id] => 11977586
[patent_doc_number] => 20170281741
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-05
[patent_title] => 'PEPTIDE AND METHOD FOR REDUCING THE PHOSPHATE REQUIREMENT AND EXCRETIION FROM FARM ANIMALS'
[patent_app_type] => utility
[patent_app_number] => 15/623450
[patent_app_country] => US
[patent_app_date] => 2017-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 11425
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623450
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/623450 | FGF-23 epitope peptides and methods of use thereof | Jun 14, 2017 | Issued |
Array
(
[id] => 12980830
[patent_doc_number] => 20170342488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-30
[patent_title] => METHODS OF USING FGF19 MODULATORS
[patent_app_type] => utility
[patent_app_number] => 15/608603
[patent_app_country] => US
[patent_app_date] => 2017-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608603
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/608603 | METHODS OF USING FGF19 MODULATORS | May 29, 2017 | Abandoned |
Array
(
[id] => 17569932
[patent_doc_number] => 11318186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-03
[patent_title] => Use of FGF21 in methods of increasing exocrine pancreatic secretion
[patent_app_type] => utility
[patent_app_number] => 16/304080
[patent_app_country] => US
[patent_app_date] => 2017-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 8132
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304080
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/304080 | Use of FGF21 in methods of increasing exocrine pancreatic secretion | May 23, 2017 | Issued |
Array
(
[id] => 14213969
[patent_doc_number] => 20190119369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-25
[patent_title] => METHOD OF TREATING OR PREVENTING LIVER CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 16/095021
[patent_app_country] => US
[patent_app_date] => 2017-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095021
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/095021 | METHOD OF TREATING OR PREVENTING LIVER CONDITIONS | Apr 20, 2017 | Abandoned |
Array
(
[id] => 14309665
[patent_doc_number] => 20190144536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE
[patent_app_type] => utility
[patent_app_number] => 16/092653
[patent_app_country] => US
[patent_app_date] => 2017-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44216
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092653
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/092653 | ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE | Apr 12, 2017 | Abandoned |
Array
(
[id] => 17274456
[patent_doc_number] => 20210380654
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/604088
[patent_app_country] => US
[patent_app_date] => 2017-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604088
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604088 | HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF | Apr 9, 2017 | Pending |
Array
(
[id] => 11949494
[patent_doc_number] => 20170253646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-07
[patent_title] => 'Functional Peptide Analogs of PEDF'
[patent_app_type] => utility
[patent_app_number] => 15/477934
[patent_app_country] => US
[patent_app_date] => 2017-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 34283
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477934
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/477934 | Functional Peptide Analogs of PEDF | Apr 2, 2017 | Abandoned |
Array
(
[id] => 16570644
[patent_doc_number] => 20210009650
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/089698
[patent_app_country] => US
[patent_app_date] => 2017-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089698
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/089698 | MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF | Mar 23, 2017 | Abandoned |
Array
(
[id] => 11728044
[patent_doc_number] => 20170189486
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-07-06
[patent_title] => 'MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/460917
[patent_app_country] => US
[patent_app_date] => 2017-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 81
[patent_figures_cnt] => 81
[patent_no_of_words] => 89672
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15460917
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/460917 | Therapeutic uses of modified FGF-21 polypeptides | Mar 15, 2017 | Issued |
Array
(
[id] => 11850282
[patent_doc_number] => 20170224774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-10
[patent_title] => 'METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH'
[patent_app_type] => utility
[patent_app_number] => 15/425872
[patent_app_country] => US
[patent_app_date] => 2017-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1914
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15425872
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/425872 | METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH | Feb 5, 2017 | Abandoned |
Array
(
[id] => 11850283
[patent_doc_number] => 20170224775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-10
[patent_title] => 'Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/424816
[patent_app_country] => US
[patent_app_date] => 2017-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 8288
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424816
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/424816 | Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF | Feb 3, 2017 | Abandoned |
Array
(
[id] => 11618221
[patent_doc_number] => 20170128408
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-11
[patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, ALEMTUZUMAB, AND ALBUMIN'
[patent_app_type] => utility
[patent_app_number] => 15/414536
[patent_app_country] => US
[patent_app_date] => 2017-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 57
[patent_figures_cnt] => 57
[patent_no_of_words] => 20275
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414536
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/414536 | Methods for treating CD52-expressing cancers using compositions comprising nanoparticle complexes of paclitaxel, alemtuzumab, and albumin | Jan 23, 2017 | Issued |
Array
(
[id] => 11618400
[patent_doc_number] => 20170128587
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-11
[patent_title] => 'NANOPARTICLE COMPLEXES OF ANTI-CD20 ANTIBODIES, ALBUMIN AND PACLITAXEL'
[patent_app_type] => utility
[patent_app_number] => 15/414526
[patent_app_country] => US
[patent_app_date] => 2017-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 56
[patent_no_of_words] => 20273
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414526
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/414526 | Nanoparticle complexes of rituximab, albumin and pacltaxel | Jan 23, 2017 | Issued |